118 related articles for article (PubMed ID: 19560596)
1. Moxifloxacin versus ethambutol in initial tuberculosis treatment.
Chang KC; Leung CC
Lancet; 2009 Jun; 373(9682):2197-8; author reply 2198-9. PubMed ID: 19560596
[No Abstract] [Full Text] [Related]
2. Moxifloxacin versus ethambutol in initial tuberculosis treatment.
Sellier P; Delcey V; Raskine L; Sanson-Le-Pors MJ; Bergmann JF
Lancet; 2009 Jun; 373(9682):2198; author reply 2198-9. PubMed ID: 19560598
[No Abstract] [Full Text] [Related]
3. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
Conde MB; Efron A; Loredo C; De Souza GR; Graça NP; Cezar MC; Ram M; Chaudhary MA; Bishai WR; Kritski AL; Chaisson RE
Lancet; 2009 Apr; 373(9670):1183-9. PubMed ID: 19345831
[TBL] [Abstract][Full Text] [Related]
4. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.
Burman WJ; Goldberg S; Johnson JL; Muzanye G; Engle M; Mosher AW; Choudhri S; Daley CL; Munsiff SS; Zhao Z; Vernon A; Chaisson RE
Am J Respir Crit Care Med; 2006 Aug; 174(3):331-8. PubMed ID: 16675781
[TBL] [Abstract][Full Text] [Related]
5. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.
Pletz MW; De Roux A; Roth A; Neumann KH; Mauch H; Lode H
Antimicrob Agents Chemother; 2004 Mar; 48(3):780-2. PubMed ID: 14982764
[TBL] [Abstract][Full Text] [Related]
6. Should moxifloxacin be substituted for isoniazid as a first-line antituberculosis drug?
Mohapatra PR
Am J Respir Crit Care Med; 2009 Oct; 180(7):686; author reply 686-7. PubMed ID: 19762595
[No Abstract] [Full Text] [Related]
7. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
Dorman SE; Johnson JL; Goldberg S; Muzanye G; Padayatchi N; Bozeman L; Heilig CM; Bernardo J; Choudhri S; Grosset JH; Guy E; Guyadeen P; Leus MC; Maltas G; Menzies D; Nuermberger EL; Villarino M; Vernon A; Chaisson RE;
Am J Respir Crit Care Med; 2009 Aug; 180(3):273-80. PubMed ID: 19406981
[TBL] [Abstract][Full Text] [Related]
8. Moxifloxacin treatment of tuberculosis.
Gosling R; Gillespie S
Antimicrob Agents Chemother; 2004 Sep; 48(9):3642; author reply 3642-3. PubMed ID: 15328148
[No Abstract] [Full Text] [Related]
9. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.
Jawahar MS; Banurekha VV; Paramasivan CN; Rahman F; Ramachandran R; Venkatesan P; Balasubramanian R; Selvakumar N; Ponnuraja C; Iliayas AS; Gangadevi NP; Raman B; Baskaran D; Kumar SR; Kumar MM; Mohan V; Ganapathy S; Kumar V; Shanmugam G; Charles N; Sakthivel MR; Jagannath K; Chandrasekar C; Parthasarathy RT; Narayanan PR
PLoS One; 2013; 8(7):e67030. PubMed ID: 23843980
[TBL] [Abstract][Full Text] [Related]
10. Fourth-generation fluoroquinolones in tuberculosis.
Rieder HL
Lancet; 2009 Apr; 373(9670):1148-9. PubMed ID: 19345815
[No Abstract] [Full Text] [Related]
11. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Winter H; Becker P; Mendel CM; Spigelman MK
Lancet; 2012 Sep; 380(9846):986-93. PubMed ID: 22828481
[TBL] [Abstract][Full Text] [Related]
12. [Study of antituberculous activity of moxifloxacin conjugate with macrophage scavenger-receptor ligand].
Azaev MSh; Agafonov AP; Bodnev SA; Blinov VM
Antibiot Khimioter; 2006; 51(11-12):7-10. PubMed ID: 18318141
[TBL] [Abstract][Full Text] [Related]
13. PanACEA: a new approach to tuberculosis research.
Burki T
Lancet Infect Dis; 2012 Mar; 12(3):184-5. PubMed ID: 22468276
[No Abstract] [Full Text] [Related]
14. Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
Zvada SP; Denti P; Geldenhuys H; Meredith S; van As D; Hatherill M; Hanekom W; Wiesner L; Simonsson US; Jindani A; Harrison T; McIlleron HM
Antimicrob Agents Chemother; 2012 Aug; 56(8):4471-3. PubMed ID: 22585223
[TBL] [Abstract][Full Text] [Related]
15. Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.
Balasubramanian V; Solapure S; Gaonkar S; Mahesh Kumar KN; Shandil RK; Deshpande A; Kumar N; Vishwas KG; Panduga V; Reddy J; Ganguly S; Louie A; Drusano GL
Antimicrob Agents Chemother; 2012 Jun; 56(6):3054-7. PubMed ID: 22470118
[TBL] [Abstract][Full Text] [Related]
16. Hepatotoxicity in the treatment of tuberculosis using moxifloxacin-containing regimens.
Roberts CH; Smith C; Breen R; Gadhok R; Murphy M; Aryee A; Cropley I; Bhagani S; Hopkins S; Lipman M
Int J Tuberc Lung Dis; 2011 Sep; 15(9):1275-6. PubMed ID: 21943863
[No Abstract] [Full Text] [Related]
17. New drug combination for TB is tested in unique trial.
Kmietowicz Z
BMJ; 2012 Jul; 345():e5060. PubMed ID: 22833631
[No Abstract] [Full Text] [Related]
18. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis.
Koh WJ; Lee SH; Kang YA; Lee CH; Choi JC; Lee JH; Jang SH; Yoo KH; Jung KH; Kim KU; Choi SB; Ryu YJ; Chan Kim K; Um S; Kwon YS; Kim YH; Choi WI; Jeon K; Hwang YI; Kim SJ; Lee YS; Heo EY; Lee J; Ki YW; Shim TS; Yim JJ
Am J Respir Crit Care Med; 2013 Oct; 188(7):858-64. PubMed ID: 23927582
[TBL] [Abstract][Full Text] [Related]
19. Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis.
Wang JY; Wang JT; Tsai TH; Hsu CL; Yu CJ; Hsueh PR; Lee LN; Yang PC
Int J Tuberc Lung Dis; 2010 Jan; 14(1):65-71. PubMed ID: 20003697
[TBL] [Abstract][Full Text] [Related]
20. Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis.
Holland DP; Sanders GD; Hamilton CD; Stout JE
PLoS One; 2012; 7(1):e30194. PubMed ID: 22272302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
